Euthymics Bioscience, Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Euthymics Bioscience, Inc.
ADC Competition Heats Up In China But Caution, Pressure Also Mount
After the anti-PD-1/L1 antibody and cell therapy rush, antibody-drug conjugates are quickly gaining attention in China as new technologies and deal-making activity heats up, but one first mover warns of potential over-crowding.
Investors Back iOmx’s Focus On Tumor Immune Evasion
The German biopharmaceutical company has been around since 2016, but now has the funding to bring its first candidate into clinical trials by late 2022
First Pre-Revenue Biotech IPO Rejection By 'China’s Nasdaq'
The STAR Market of the Shanghai Stock Exchange has called a halt to the potentially third-largest biotech IPO this year in an apparent deterrent to the in-licensing model.
Finance Watch: Venture Capital, Debt Financings Led Fundraising Surge In Q2
New VC deals include a $60m series C-1 round for DiCE Molecules a day before it filed paperwork to support a $100m IPO and a $100m financing for China’s IONOVA Life Science. Also, RenovoRx was the 84th company to go public in the US this year and ADC Therapeutics executed a $325m royalty deal.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- DOV Pharmaceutical, Inc.